148 related articles for article (PubMed ID: 6354812)
1. Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice.
Lord JM; Atkins TW; Bailey CJ
Diabetologia; 1983 Aug; 25(2):108-13. PubMed ID: 6354812
[TBL] [Abstract][Full Text] [Related]
2. Effect of age on hepatocyte and soleus muscle insulin receptor binding in lean and genetically obese diabetic (ob/ob) mice.
Lord JM; Atkins TW
Diabetes Res; 1985 Sep; 2(5):259-65. PubMed ID: 3905189
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-benzoyl-D-phenylalanine and metformin on insulin receptors in neonatal streptozotocin-induced diabetic rats: studies on insulin binding to erythrocytes.
Ashokkumar N; Pari L; Rao ChA
Arch Physiol Biochem; 2006 Jul; 112(3):174-81. PubMed ID: 17132543
[TBL] [Abstract][Full Text] [Related]
4. Postreceptor effect of metformin on insulin action in mice.
Lord JM; Puah JA; Atkins TW; Bailey CJ
J Pharm Pharmacol; 1985 Nov; 37(11):821-3. PubMed ID: 2867167
[TBL] [Abstract][Full Text] [Related]
5. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations.
Rossetti L; DeFronzo RA; Gherzi R; Stein P; Andraghetti G; Falzetti G; Shulman GI; Klein-Robbenhaar E; Cordera R
Metabolism; 1990 Apr; 39(4):425-35. PubMed ID: 2157941
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin on glucose metabolism in mouse soleus muscle.
Bailey CJ; Puah JA
Diabete Metab; 1986 Aug; 12(4):212-8. PubMed ID: 3770275
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes.
Lord JM; White SI; Bailey CJ; Atkins TW; Fletcher RF; Taylor KG
Br Med J (Clin Res Ed); 1983 Mar; 286(6368):830-1. PubMed ID: 6403102
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
9. Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients.
Rizkalla SW; Elgrably F; Tchobroutsky G; Slama G
Diabete Metab; 1986 Aug; 12(4):219-24. PubMed ID: 3533670
[TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on testicular expression and localization of leptin receptor and levels of leptin in the diabetic mice.
Annie L; Jeremy M; Gurusubramanian G; Derkach KV; Shpakov AO; Roy VK
Mol Reprod Dev; 2020 May; 87(5):620-629. PubMed ID: 32249489
[TBL] [Abstract][Full Text] [Related]
11. Effect of fasting and streptozotocin in the obese-hyperglycemic (ob/ob) mouse. Apparent lack of a direct relationship between insulin binding and insulin effects.
Le Marchand Y; Loten EG; Assimacopoulos-Jeannet F; Forgue ME; Freychet P; Jeanrenaud B
Diabetes; 1977 Jun; 26(6):582-90. PubMed ID: 140828
[TBL] [Abstract][Full Text] [Related]
12. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance.
Saad MJ; Araki E; Miralpeix M; Rothenberg PL; White MF; Kahn CR
J Clin Invest; 1992 Nov; 90(5):1839-49. PubMed ID: 1331176
[TBL] [Abstract][Full Text] [Related]
13. Treatment of streptozotocin-diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity and demonstrates that insulin does not exert this action through the inhibitory guanine nucleotide regulatory protein Gi.
Gawler D; Milligan G; Houslay MD
Biochem J; 1988 Jan; 249(2):537-42. PubMed ID: 3124829
[TBL] [Abstract][Full Text] [Related]
14. The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats.
Salman ZK; Refaat R; Selima E; El Sarha A; Ismail MA
Eur J Pharmacol; 2013 Aug; 714(1-3):448-55. PubMed ID: 23845213
[TBL] [Abstract][Full Text] [Related]
15. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.
Chen Y; Ren Q; Zhou Z; Deng L; Hu L; Zhang L; Li Z
Br J Pharmacol; 2020 May; 177(10):2286-2302. PubMed ID: 31971610
[TBL] [Abstract][Full Text] [Related]
16. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
[TBL] [Abstract][Full Text] [Related]
17. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic tolbutamide administration on normal and obese-hyperglycemic mice: evidence for post-receptor potentiation of insulin action.
Poyet C; Feldman JM
Res Commun Chem Pathol Pharmacol; 1982 Mar; 35(3):355-76. PubMed ID: 7043679
[TBL] [Abstract][Full Text] [Related]
19. The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Lule KO; Akarsu E; Sayiner ZA; Lule NO; Balci SO; Demirel C; Bozdag Z; Korkmaz M; Yilmaz I
Inflammopharmacology; 2022 Feb; 30(1):243-250. PubMed ID: 35072848
[TBL] [Abstract][Full Text] [Related]
20. Insulin action and binding in isolated hepatocytes from fasted, streptozotocin-diabetic, and older, spontaneously obese rats.
Cech JM; Freeman RB; Caro JF; Amatruda JM
Biochem J; 1980 Jun; 188(3):839-45. PubMed ID: 7008780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
